Researchers develop machine learning model that uses retinal scans to identify mild cognitive impairment

Article

The machine learning model analyzes retinal images and associated data and recognizes specific features to identify individuals with mild cognitive impairment.

©Elnur / Adobe.stock.com

The machine learning model analyzes retinal images and associated data and recognizes specific features to identify individuals with mild cognitive impairment. (Image Credit: Elnur/Adobe Stock)

Researchers at Duke Health developed a machine learning model with the ability to differentiate normal cognition from mild cognitive impairment using retinal images from the eye.

According to a Duke University Medical Center news release, the model analyzes retinal images and associated data and recognizes specific features to identify individuals with mild cognitive impairment.

According to the study,1 which was published in Ophthalmology Science, the model demonstrates the potential for a non-invasive and inexpensive method of identifying the early signs of cognitive impairment that could progress to Alzheimer’s disease.

“This is particularly exciting work because we have previously been unable to differentiate mild cognitive impairment from normal cognition in previous models,” said senior author Sharon Fekrat, MD, professor in Duke’s departments of Ophthalmology and Neurology and associate professor in the Department of Surgery. “This work brings us one step closer to detecting cognitive impairment earlier before it progresses to Alzheimer’s dementia.”

According to the university’s news release, Fekrat and colleagues previously developed a model that used retinal scans and other data to successfully identify patients with a known Alzheimer’s diagnosis. The scans – based on optical coherence tomography (OCT) and OCT angiography (OCTA) -- detected structural changes in the neurosensory retina and its microvasculature among Alzheimer’s patients.1

The researchers noted in the news release that their current work expands on that work, using machine learning techniques to detect mild cognitive impairment, which is often a precursor to Alzheimer’s. The new model identifies specific features in the OCT and OCTA images that signal the presence of cognitive impairment, along with patient data such as age, sex, visual acuity, and years of education and quantitative data from the images themselves.1

According to the news release, researchers found the model analyzed retinal pictures and images along with quantitative data to differentiate people with normal cognition from those with a diagnosis of mild cognitive impairment with a sensitivity of 79% and specificity of 83%.

“This is the first study to use retinal OCT and OCTA images to distinguish people with mild cognitive impairment from individuals with normal cognition,” co-first author C. Ellis Wisely, MD, assistant professor in the Department of Ophthalmology, said in a statement.

“Having a non-invasive and less expensive means to reliably identify these patients is increasingly important, particularly as new therapies for Alzheimer’s disease may become available,” Wisely said in the news release.

“The retina is a window to the brain, and machine learning algorithms that leverage non-invasive and cost-effective retinal imaging to assess neurological health can be a potent tool to screen patients at scale,” said co-lead author Alexander Richardson, a student in the Eye Multimodal Imaging in Neurodegenerative Disease lab at Duke.

According to the news release, the study received some support from the Alzheimer’s Drug Discovery Foundation.

Reference:
  1. C. Ellis Wisely, MD, MBA; Alexander Richardson, Ricardo Henao, PhD, Andy J. Liu, MD, Dilraj S. Grewal, MD, FASRS, Sharon Fekrat, MD, FASRS. A convolutional neural network using multimodal retinal imaging for differentiation of mild cognitive impairment from normal cognition. Ophthalmology Science. Published June 25, 2023. DOI: https://doi.org/10.1016/j.xops.2023.100355
Related Videos
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 2 - "FDA-approved Therapies for Geographic Atrophy"
Video 1 - "Geographic Atrophy: Overview, Diagnosis, and Progression"
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2024 MJH Life Sciences

All rights reserved.